Shanghai Labway Clinical Laboratory Co., Ltd.

Shenzhen Stock Exchange 301060.SZ

Shanghai Labway Clinical Laboratory Co., Ltd. EBIT Margin for the year ending December 31, 2023: -7.43%

Shanghai Labway Clinical Laboratory Co., Ltd. EBIT Margin is -7.43% for the year ending December 31, 2023, a -134.03% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Shanghai Labway Clinical Laboratory Co., Ltd. EBIT Margin for the year ending December 31, 2022 was 21.83%, a 20.59% change year over year.
Shanghai Labway Clinical Laboratory Co., Ltd. EBIT Margin for the year ending December 31, 2021 was 18.10%, a 37.75% change year over year.
Shanghai Labway Clinical Laboratory Co., Ltd. EBIT Margin for the year ending December 31, 2020 was 13.14%, a 6.69% change year over year.
Shanghai Labway Clinical Laboratory Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 12.32%, a 17.83% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Shenzhen Stock Exchange: 301060.SZ

Shanghai Labway Clinical Laboratory Co., Ltd.

CEO	Mr. Weixiong Zeng
IPO Date	Sept. 13, 2021
Location	China
Headquarters	Building 1, Lane 268
Employees	1,487
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Hardware & Electronics Personal Care Professional Services Specialty Retail

Description

Shanghai Labway Clinical Laboratory Co., Ltd. offers sales services for in vitro diagnostic products; and medical laboratory services. Shanghai Labway Clinical Laboratory Co., Ltd. was founded in 1993 and is based in Shanghai, China.

Key trends

Past 5 years